Related Experiment Video

Updated: Jun 23, 2026

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres
06:52

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Published on: July 22, 2020

Guanylyl cyclase C in colorectal cancer: susceptibility gene and potential therapeutic target

Jieru E Lin1, Peng Li, Giovanni M Pitari

  • 1Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, 132 South 10th Street, 1170 Main, Philadelphia, PA 19107, USA. Egeria.Lin@jefferson.edu

Future Oncology (London, England)
|May 20, 2009
PubMed

Insights

Guanylyl cyclase C (GCC) loss drives colorectal tumor growth by disrupting cell homeostasis. Hormone replacement therapy targeting GCC offers a promising strategy for colorectal cancer prevention and treatment.

Area of Science:

  • Oncology
  • Gastroenterology
  • Molecular Biology

Background:

  • Colorectal cancer remains a major global health challenge with limited therapeutic options despite advances in understanding its molecular mechanisms.
  • Current therapeutic resistance is linked to the complex interplay of signaling pathways and a lack of insight into early tumorigenic processes.
  • Guanylyl cyclase C (GCC), a receptor for intestinal hormones, is lost early in colorectal transformation, suggesting a role in homeostasis.

Purpose of the Study:

  • To investigate the role of Guanylyl cyclase C (GCC) signaling in colorectal tumorigenesis.
  • To explore the potential of hormone-replacement therapy for colorectal cancer prevention and treatment.

Main Methods:

  • Analysis of molecular mechanisms underlying colorectal cancer initiation and progression.
  • Examination of the function of Guanylyl cyclase C (GCC) in intestinal homeostasis and tumorigenesis.
  • Evaluation of hormone-replacement therapy as a therapeutic strategy.

Main Results:

  • Loss of Guanylyl cyclase C (GCC) signaling dysregulates cellular replicative and bioenergetic circuits, promoting genomic instability and tumor development.
  • Early loss of GCC is a hallmark of colorectal transformation.
  • Compensatory upregulation of GCC in response to hormone loss presents a therapeutic target.

Conclusions:

  • Dysregulation of Guanylyl cyclase C (GCC) signaling is a critical factor in colorectal cancer development.
  • Targeting GCC with hormone-replacement therapy represents a novel and potentially effective approach for preventing and treating colorectal tumors.

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Establishment of Coloproctitis Cancer Model in Mice and Evaluation of Therapeutic Effect of Chinese Medicine06:24

Establishment of Coloproctitis Cancer Model in Mice and Evaluation of Therapeutic Effect of Chinese Medicine

Published on: October 13, 2023

Related Concept Videos

GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...